Multiple sclerosis interferon beta therapies

Rotondi M, Oliviero A, Profice P, Mone CM, Biondi B, Del Buono A, Mazziotti G, Sinisi AM, Bellastella A, Carella C. Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis. J Endocrinol Invest 1998 21(ll) 748-52. 

Zephir H, De Seze J, Stojkovic T, Delisse B, Ferriby D, Cabaret M, Vermersch P. Multiple sclerosis and depression influence of interferon beta therapy. Mult Scler 2003 9(3) 284—8. 

Bayas A, Rieckmann P. Managing the adverse effects of interferon-beta therapy in multiple sclerosis. Drug Saf 2000 22(2) 149-59. 

Hoffmann S, Cepok S, Grummet V, Lehmann-Hom K, Hackermuller J, Stadler PE, Hartung HP, Berthele A, Deisenhammer F, Wassmuth R, Hemmer B (2008) HLA-DRB1 0401 and HLA-DRB1 0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 83 219-227... 

Gl. Galboiz, Y., Shapiro, S., Lahat, N., Rawashdeh, H., and Miller, A., Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann. Neurol. 50, 443-451 (2001). 

Gavasso S, Gjtatsen B, Anderssen E, Myhr K, Vedeler C. Immunogenic effects of recombinant interferon-beta therapy dismpt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis. Mult Scler. 2012 18 1116-24. 

Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownschei-dle CM, Murray TJ et al. Intramuscular interferon beta-1 a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000 343(13) 898-904. 

F. Place in therapy Avonex has shown significant advantages over interferon beta-lb (Betaseron) in the treatment of multiple sclerosis. It is administered once a week rather than every other day, and it is not associated with the high incidence of injection site skin necrosis reported with interferon beta-lb in some studies. It appears (based on indirect comparison) at... 

E Role in therapy Betaseron is useful for reducing symptomatic exacerbation in multiple sclerosis (MS) patients with relapsing-remitting disease. The drug should be considered in patients with ch-nically deflnite or laboratory-supported definite disease. It is not indicated in those patients with primary progressive MS. Interferon beta-la (Avonex) has also demonstrated activity in MS patients. 

Caraccio N, Dardano A, Manfredonia F, Manca L, Pasquali L, Iudice A, Murri L, Ferrannini E, Monzani F. Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-beta la or lb therapy predictive factors of thyroid disease development and duration. J Clin Endocrinol Metab 2005 90(7) 4133-7. 

Patten SB, Francis G, Metz LM, Lopez-Bresnahan M, Chang P, Curtin F. The relationship between depression and interferon beta-la therapy in patients with multiple sclerosis. Mult Scler 2005 11 175-81. 

Martinez-Cacenes EM (1998) Amelioration of flu-like symptoms at the onset of interferon beta-lb therapy in multiple sclerosis by low dose oral steroids is related to a decrease in interleukin-6 mduc-tion. Arm Neurol 44(4) 682-685. 

Patti F, Amato MP, Filippi M, Gallo P, Trojano M, Comi GC (2004) A double blind placebo-controlled phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination CYCLIN. J Neurol 223(1) 69—71. 

Reess J, Haas J, Gabriel K, Fuhlrott A, FiolaM (2002) Both paracetamol and ibuprofen are equally effective in managing flu-hke symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-la (AVONEX) therapy. Mult Scler 8(1) 15-18. 

Smith DR, Weinstock-Guttman B, Cohen JA, Wei X, Gutmann C, Bakshi R, Olek M, Stone L, Greenberg S, Stuart D, Orav J, Stuart W, Weiner H (2005) A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta. Mult Scler 5 573-582. 

Herrera WG, Balizet LB, Harberts SW, Brown ST. Occurrence of a TTP-like syndrome in two women receiving beta interferon therapy for relapsing multiple sclerosis. Neurology 1999 52 135. 

Immunologic Two patients developed systemic immune responses 1-2 months after withdrawal of interferon beta, characterized by mouth ulcers, a photosensitivity rash, and transient formation of autoantibodies that required glucocorticoid therapy for resolution in an open baseline versus treatment phase II clinical trial of daclizumab in patients with multiple sclerosis and an inadequate response to interferon beta [211 ]. In rare cases severe hypersensitivity reactions after daclizumab have been reported. 

In a 6-month randomised, double-blind trial to evaluate the effectiveness of two doses intramuscular vitamin D3 therapy (600,000 lU and 300,000111 weekly) in the treatment of tropical calcific pancreatitis, neither h5rpercalcaemia nor hypervitaminosis D was observed Both low- and high-dose vitamin D3 supplementations (800lU and 4370 lU daily) in multiple sclerosis patients being treated with interferon beta were not associated with any serious adverse events [46 ]. 

---